Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

• Published in: Clinical cancer research Vol. 27; no. 2; pp. 438 - 446
• Main Authors: Hollebecque, Antoine, Salvagni, Stefania, Plummer, Ruth, Isambert, Nicolas, Niccoli, Patricia, Capdevila, Jaume, Curigliano, Giuseppe, Moreno, Victor, Martin-Romano, Patricia, Baudin, Eric, Arias, Marina, Mora, Sheila, de Alvaro, Juan, Di Martino, Jorge, Parra-Palau, Josep L, Sánchez-Pérez, Tania, Aronchik, Ida, Filvaroff, Ellen H, Lamba, Manisha, Nikolova, Zariana, de Bono, Johann S
• Format: Journal Article
• Language: English
• Published: United States 15.01.2021
• Subjects: Adult; Aged; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue - chemically induced; Female; Humans; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - pathology; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms - drug therapy; Neoplasms - pathology; Organic Chemicals - adverse effects; Organic Chemicals - pharmacokinetics; Organic Chemicals - therapeutic use; Thrombocytopenia - chemically induced; Treatment Outcome; Young Adult

Lysine-specific demethylase 1 (LSD1) is implicated in multiple tumor types, and its expression in cancer stem cells is associated with chemoresistance. CC-90011 is a potent, selective, and reversible oral LSD1 inhibitor. We examined CC-90011 in advanced solid tumors and relapsed/refractory (R/R) non...